The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic

被引：15

作者：

O'Brien, E ^{[1
]}

Bouchier-Hayes, D ^{[1
]}

Fitzgerald, D ^{[1
]}

Atkins, N ^{[1
]}

机构：

[1] Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland

来源：

LANCET | 1998年 / 352卷 / 9141期

关键词：

D O I：

10.1016/S0140-6736(97)09026-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1700 / 1702

页数：3

共 13 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2]

Atkins N, 1998, J HYPERTENS, V16, pS198

[3] CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke [J].

Chen, ZM ;

Hui, JM ;

Liu, LS ;

Liu, ZM ;

Peto, R ;

Sandercock, P ;

Wang, WQ ;

Wang, YX ;

Wang, ZB ;

Xie, JX ;

You, GX ;

Zhang, FL ;

Zhang, HQ ;

Zhao, ZY .

LANCET, 1997, 349 (9066) :1641-1649

[4] Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced - A randomized intervention study [J].

Fagerberg, B ;

Wikstrand, J ;

Berglund, G ;

Samuelsson, O ;

Agewall, S .

AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (01) :14-22

[5]

Gensini GF, 1998, EUR HEART J, V19, pA53

[6] Plasma homocysteine as a risk factor for vascular disease - The European concerted action project [J].

Graham, IM ;

Daly, LE ;

Refsum, HM ;

Robinson, K ;

Brattstrom, LE ;

Ueland, PM ;

PalmaReis, RJ ;

Boers, GHJ ;

Sheahan, RG ;

Israelsson, B ;

Uiterwaal, CS ;

Meleady, R ;

McMaster, D ;

Verhoef, P ;

Witteman, J ;

Rubba, P ;

Bellet, H ;

Wautrecht, JC ;

deValk, HW ;

Luis, ACS ;

ParrotRoulaud, FM ;

Tan, KS ;

Higgins, I ;

Garcon, D ;

Medrano, MJ ;

Candito, M ;

Evans, AE ;

Andria, G .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (22) :1775-1781

[7] Cardiovascular risk in hypertension: implications of the Sheffield Table for lipid-lowering strategy [J].

Hasnain, S ;

Webster, J ;

McLay, JS .

JOURNAL OF HUMAN HYPERTENSION, 1998, 12 (07) :469-471

[8]

MOHER M, 1997, BMJ-BRIT MED J, V515, P69

[9] The rationale for differing national recommendations for the treatment of hypertension [J].

Ramsay, LE ;

Wallis, EJ ;

Yeo, WM ;

Jackson, PR .

AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (06) :79S-88S

[10] The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [J].

Sacks, FM ;

Pfeffer, MA ;

Moye, LA ;

Rouleau, JL ;

Rutherford, JD ;

Cole, TG ;

Brown, L ;

Warnica, JW ;

Arnold, JMO ;

Wun, CC ;

Davis, BR ;

Braunwald, E .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1001-1009

← 1 2 →